Metoclopramide (Reglan) Can Cause Bradycardia and Cardiac Arrest
Yes, metoclopramide can cause severe bradycardia and even cardiac arrest, though this is a rare but serious adverse effect that requires immediate recognition and treatment with atropine, discontinuation of the drug, and supportive care.
Mechanism and Risk Profile
Metoclopramide's cardiac toxicity likely stems from its sodium channel blocking properties (similar to procainamide) rather than its dopamine antagonist effects 1. The FDA drug label does not prominently list cardiac arrest as a precaution or adverse reaction, which may contribute to underrecognition of this serious complication 2.
Key Clinical Characteristics:
- Onset: Bradycardia typically occurs within 1 minute of IV administration 3, 1
- Severity: Can progress rapidly from severe bradycardia (4 beats/min) to asystole 3, 1
- Route-dependent: Most reported cases involve intravenous administration 1, 4
- Not dose-related: Can occur at standard therapeutic doses (10 mg IV) 1
High-Risk Populations
Elderly patients are particularly vulnerable, even without significant cardiac history 4. Other potential risk factors include:
- Coronary artery disease 1
- Hypertension (metoclopramide releases catecholamines) 2
- Congestive heart failure 2
- Concurrent use of other medications affecting cardiac conduction
Immediate Management Algorithm
If Bradycardia Develops:
- Discontinue metoclopramide immediately
- Atropine 0.5-1 mg IV every 3-5 minutes up to 3 mg total 5, 6, 7
- If atropine fails, consider:
- Transcutaneous pacing if refractory to medications 5, 6
- CPR if cardiac arrest occurs 3, 1
Post-Resuscitation Care:
Monitor for secondary arrhythmias including:
- Supraventricular tachycardia
- Atrial fibrillation
- ST segment changes indicating myocardial injury 1
Clinical Pitfalls
Critical warning: One case report documented five separate episodes of asystole occurring immediately after each of five 10 mg IV doses of metoclopramide, demonstrating reproducibility of this adverse effect 1. This underscores the importance of:
- Slow IV administration when metoclopramide must be given
- Continuous cardiac monitoring during and immediately after IV administration
- Avoiding repeat dosing if any cardiac effects occur
- Considering alternative antiemetics in high-risk patients
Alternative Considerations
Given the cardiac risks, particularly with IV administration in elderly or cardiac patients, consider:
- Ondansetron (though has QT prolongation risk)
- Oral metoclopramide (lower risk than IV)
- Other antiemetic classes depending on indication
The literature contains at least 8 documented cases of cardiac arrest from metoclopramide 1, suggesting this is an underrecognized and underreported adverse effect that warrants heightened clinical vigilance and mandatory cardiac monitoring during IV administration.